Literature DB >> 17020996

Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization.

Séverine Colas1, Karine Mahéo, Fabrice Denis, Caroline Goupille, Claude Hoinard, Pascal Champeroux, François Tranquart, Philippe Bougnoux.   

Abstract

PURPOSE: To investigate whether dietary docosahexaenoic acid (DHA), a peroxidizable polyunsaturated omega-3 fatty acids, sensitizes rat mammary tumors to anthracyclines and whether its action interferes with tumor vascularization, a critical determinant of tumor growth. EXPERIMENTAL
DESIGN: Female Sprague-Dawley rats were initiated by N-methylnitrosourea to develop mammary tumors and then assigned to a control group (n = 18), receiving a supplementation of palm oil, or to a DHA group (n = 54), supplemented with a microalgae-produced oil (DHASCO, 1.5 g/d). The DHA group was equally subdivided into three subgroups with addition of different amounts of alpha-tocopherol. Epirubicin was injected weekly during 6 weeks after the largest tumor reached 1.5 cm(2), and subsequent changes in the tumor surface were evaluated. Tumor vascularization was assessed by power Doppler sonography before and during chemotherapy.
RESULTS: DHA and alpha-tocopherol were readily absorbed and incorporated into rat tissues. Epirubicin induced a 45% mammary tumor regression in the DHA-supplemented group, whereas no tumor regression was observed in the control group. In the DHA group, before chemotherapy was initiated, tumor vascular density was 43% lower than in the control group and remained lower during chemotherapy. Enhancement of epirubicin efficacy by DHA was abolished in a dose-dependent manner by alpha-tocopherol, and the same trend was observed for DHA-induced reduction in tumor vascular density.
CONCLUSIONS: Dietary DHA supplementation led to a reduction in tumor vascularization before the enhancement of any response to anthracyclines, suggesting that DHA chemosensitizes mammary tumors through an inhibition of the host vascular response to the tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020996     DOI: 10.1158/1078-0432.CCR-06-0386

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Determinants of DHA incorporation into tumor tissue during dietary DHA supplementation.

Authors:  Nawale Hajjaji; Valérie Schubnel; Philippe Bougnoux
Journal:  Lipids       Date:  2011-06-03       Impact factor: 1.880

2.  Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model.

Authors:  Renata S Fernandes; Juliana O Silva; Samuel V Mussi; Sávia C A Lopes; Elaine A Leite; Geovanni D Cassali; Valbert N Cardoso; Danyelle M Townsend; Patrick M Colletti; Lucas A M Ferreira; Domenico Rubello; André L B de Barros
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

Review 3.  Contribution of n-3 Long-Chain Polyunsaturated Fatty Acids to the Prevention of Breast Cancer Risk Factors.

Authors:  Mostefa Fodil; Vincent Blanckaert; Lionel Ulmann; Virginie Mimouni; Benoît Chénais
Journal:  Int J Environ Res Public Health       Date:  2022-06-28       Impact factor: 4.614

4.  Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.

Authors:  Samuel V Mussi; Rupa Sawant; Federico Perche; Mônica C Oliveira; Ricardo B Azevedo; Lucas A M Ferreira; Vladimir P Torchilin
Journal:  Pharm Res       Date:  2014-02-13       Impact factor: 4.200

Review 5.  Omega-3 fatty acids for breast cancer prevention and survivorship.

Authors:  Carol J Fabian; Bruce F Kimler; Stephen D Hursting
Journal:  Breast Cancer Res       Date:  2015-05-04       Impact factor: 6.466

6.  Polymeric nanocapsules prevent oxidation of core-loaded molecules: evidence based on the effects of docosahexaenoic acid and neuroprostane on breast cancer cells proliferation.

Authors:  Jérôme Roy; Liliam Teixeira Oliveira; Camille Oger; Jean-Marie Galano; Valerie Bultel-Poncé; Sylvain Richard; Andrea Grabe Guimaraes; José Mário Carneiro Vilela; Margareth Spangler Andrade; Thierry Durand; Pierre Besson; Vanessa Carla Furtado Mosqueira; Jean-Yves Le Guennec
Journal:  J Exp Clin Cancer Res       Date:  2015-12-21

Review 7.  Current evidence linking polyunsaturated Fatty acids with cancer risk and progression.

Authors:  Maria Azrad; Chelsea Turgeon; Wendy Demark-Wahnefried
Journal:  Front Oncol       Date:  2013-09-04       Impact factor: 6.244

8.  Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial.

Authors:  P Bougnoux; N Hajjaji; M N Ferrasson; B Giraudeau; C Couet; O Le Floch
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

Review 9.  Dietary docosahexaenoic Acid (22:6) incorporates into cardiolipin at the expense of linoleic Acid (18:2): analysis and potential implications.

Authors:  Colin H Cortie; Paul L Else
Journal:  Int J Mol Sci       Date:  2012-11-21       Impact factor: 5.923

10.  Prospective associations between plasma saturated, monounsaturated and polyunsaturated fatty acids and overall and breast cancer risk - modulation by antioxidants: a nested case-control study.

Authors:  Camille Pouchieu; Véronique Chajès; François Laporte; Emmanuelle Kesse-Guyot; Pilar Galan; Serge Hercberg; Paule Latino-Martel; Mathilde Touvier
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.